Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model

Antiviral Research

Volumn 112, Issue , 2014, Pages 38-46

  Tollefson, Ann E ^a   Spencer, Jacqueline F ^a   Ying, Baoling ^a   Buller, R Mark L ^a   Wold, William S M ^a   Toth, Karoly ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Antiviral; Brincidofovir; Cidofovir; Hamster; Ribavirin

Indexed keywords

BRINCIDOFOVIR; CIDOFOVIR; CYCLOPHOSPHAMIDE; RIBAVIRIN; ALANINE AMINOTRANSFERASE; CYTOSINE; PHOSPHONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN ADENOVIRUS 5; HUMAN ADENOVIRUS INFECTION; HUMAN CELL; LIVER TOXICITY; NONHUMAN; SYRIAN HAMSTER; VIRUS REPLICATION; ADENOVIRIDAE INFECTIONS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BODY WEIGHT; CELL LINE; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; HUMAN ADENOVIRUS C; IMMUNOCOMPROMISED PATIENT; LIVER; MESOCRICETUS; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADENOVIRIDAE; CRICETINAE; MESOCRICETUS AURATUS;

ADENOVIRIDAE INFECTIONS; ADENOVIRUSES, HUMAN; ALANINE TRANSAMINASE; ANIMALS; BODY WEIGHT; CELL LINE; CYTOSINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LIVER; MESOCRICETUS; ORGANOPHOSPHONATES; RIBAVIRIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84908441171     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.10.005     Document Type: Article

References (34)

1. CDER, F., 2005. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.
2. D.M. Coen, and D.D. Richman Antiviral agents D.M. Knipe, P.M. Howley, Fields Virology sixth ed. 2013 Lippincott Williams & Wilkins 338 373
3. E. De Clercq The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond Biochem. Pharmacol. 82 2011 99 109
4. D. Dhar, K. Toth, and W.S. Wold Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters Cancer Gene Ther. 21 2014 171 178
5. D.F. Florescu, S.A. Pergam, M.N. Neely, F. Qiu, C. Johnston, S. Way, J. Sande, D.A. Lewinsohn, J.A. Guzman-Cottrill, M.L. Graham, G. Papanicolaou, J. Kurtzberg, J. Rigdon, W. Painter, H. Mommeja-Marin, R. Lanier, M. Anderson, and C. van der Horst Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients Biol. Blood Marrow Transplant. 18 2012 731 738
6. A.N. Freiberg, M.N. Worthy, B. Lee, and M.R. Holbrook Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection J. Gen. Virol. 91 2010 765 772
7. C.B. Hartline, K.M. Gustin, W.B. Wan, S.L. Ciesla, J.R. Beadle, K.Y. Hostetler, and E.R. Kern Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro J. Infect. Dis. 191 2005 396 399
8. N. Hatakeyama, N. Suzuki, T. Kudoh, T. Hori, N. Mizue, and H. Tsutsumi Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant Pediatr. Infect. Dis. J. 22 2003 928 929
9. K.Y. Hostetler Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art Antiviral Res. 82 2009 A84 A98
10. M.G. Ison Adenovirus infections in transplant recipients Clin. Infect. Dis. 43 2006 331 339
11. H. Izzedine, V. Launay-Vacher, and G. Deray Antiviral drug-induced nephrotoxicity Am. J. Kidney Dis. 45 2005 804 817
12. H. Kaneko, S. Mori, O. Suzuki, T. Iida, S. Shigeta, M. Abe, S. Ohno, K. Aoki, and T. Suzutani The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir Antiviral Res. 61 2004 63 66
13. L. Lenaerts, E. Verbeken, E. De Clercq, and L. Naesens Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections Antimicrob. Agents Chemother. 49 2005 4689 4699
14. D.L. Lichtenstein, J.F. Spencer, K. Doronin, D. Patra, J. Meyer, E.V. Shashkova, M. Kuppuswamy, D. Dhar, M.A. Thomas, A.E. Tollefson, L.A. Zumstein, W.S.M. Wold, and K. Toth An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector Cancer Gene Ther. 16 2009 644 654
15. W.C. Magee, K.A. Aldern, K.Y. Hostetler, and D.H. Evans Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand Antimicrob. Agents Chemother. 52 2008 586 597
16. W.C. Magee, K.Y. Hostetler, and D.H. Evans Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate Antimicrob. Agents Chemother. 49 2005 3153 3162
17. F.M. Marty, D.J. Winston, S.D. Rowley, E. Vance, G.A. Papanicolaou, K.M. Mullane, T.M. Brundage, A.T. Robertson, S. Godkin, H. Mommeja-Marin, M. Boeckh C.M.X.C.S Group CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation N. Engl. J. Med. 369 2013 1227 1236
18. S. Matthes-Martin, H. Boztug, and T. Lion Diagnosis and treatment of adenovirus infection in immunocompromised patients Expert Rev. Anti Infect. Ther. 11 2013 1017 1028
19. S. Matthes-Martin, T. Feuchtinger, P.J. Shaw, D. Engelhard, H.H. Hirsch, C. Cordonnier, and P. Ljungman European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011) Transpl. Infect. Dis. 14 2012 555 563
20. F. Morfin, S. Dupuis-Girod, E. Frobert, S. Mundweiler, D. Carrington, P. Sedlacek, M. Bierings, P. Cetkovsky, A.C. Kroes, M.J. van Tol, and D. Thouvenot Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone Antivir. Ther. 14 2009 55 61
21. F. Morfin, S. Dupuis-Girod, S. Mundweiler, D. Falcon, D. Carrington, P. Sedlacek, M. Bierings, P. Cetkovsky, A.C. Kroes, M.J. van Tol, and D. Thouvenot In vitro susceptibility of adenovirus to antiviral drugs is species-dependent Antivir. Ther. 10 2005 225 229
22. K. Paolino, J. Sande, E. Perez, B. Loechelt, B. Jantausch, W. Painter, M. Anderson, T. Tippin, E.R. Lanier, T. Fry, and R.L. DeBiasi Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001 J. Clin. Virol. 50 2011 167 170
23. M. Refaat, D. McNamara, J. Teuteberg, R. Kormos, K. McCurry, M. Shullo, Y. Toyoda, and C. Bermudez Successful cidofovir treatment in an adult heart transplant recipient with severe adenovirus pneumonia J. Heart Lung Transplant. 27 2008 699 700
24. E.G. Romanowski, and Y.J. Gordon Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model Invest. Ophthalmol. Vis. Sci. 41 2000 460 463
25. U. Sandkovsky, L. Vargas, and D.F. Florescu Adenovirus: current epidemiology and emerging approaches to prevention and treatment Curr. Infect. Dis. Rep. 16 2014 416
26. D.P. Shah, S.S. Ghantoji, V.E. Mulanovich, E.J. Ariza-Heredia, and R.F. Chemaly Management of respiratory viral infections in hematopoietic cell transplant recipients Am. J. Blood Res. 2 2012 203 218
27. M.A. Thomas, J.F. Spencer, K. Toth, J.E. Sagartz, N. Phillips, and W.S.M. Wold Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model Mol. Ther. 16 2008 1665 1673
28. M.A. Thomas, J.F. Spencer, and W.S.M. Wold Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors A.E. Tollefson, W.S.M. Wold, Methods in Molecular Medicine second ed. 2007 Humana Press Totowa 169 183
29. A.E. Tollefson, M. Kuppuswamy, E.V. Shashkova, K. Doronin, and W.S. Wold Preparation and titration of CsCl-banded adenovirus stocks Methods Mol. Med. 130 2007 223 235
30. K. Toth, J.F. Spencer, D. Dhar, J.E. Sagartz, R.M. Buller, G.R. Painter, and W.S.M. Wold Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model Proc. Natl. Acad. Sci. U.S.A. 105 2008 7293 7297
31. W.S. Wold, and K. Toth Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds Adv. Cancer Res. 115 2012 69 92
32. W.S.M. Wold, and M.G. Ison Adenoviruses D.M. Knipe, P.M. Howley, Fields Virology 2013 Lippincott Williams & Wilkins Philadelphia, PA 1732
33. X. Xiong, J.L. Smith, and M.S. Chen Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation Antimicrob. Agents Chemother. 41 1997 594 599
34. B. Ying, K. Toth, J.F. Spencer, J. Meyer, A.E. Tollefson, D. Patra, D. Dhar, E.V. Shashkova, M. Kuppuswamy, K. Doronin, M.A. Thomas, L.A. Zumstein, W.S.M. Wold, and D.L. Lichtenstein INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies Cancer Gene Ther. 16 2009 625 637